acute myeloid leukemia

Research in Review

Immunotherapy Diminishes Regulatory T-Cells, Improves Outcomes in AML

07/20/2017

JCP Editors

Immunotherapy after complete remission in acute myeloid leukemia (AML) is associated with decreasing levels of regulatory T-cells, which leads to favorable clinical outcomes, according to research published in Cancer...

...

07/20/2017

Journal of Clinical Pathways

Research in Review

Altered B-Cell Composition May Impact Immunotherapy Effectiveness in AML

07/13/2017

JCP Editors

Initial chemotherapy often alters B-cell composition and immunity in patients with acute myeloid leukemia (AML), which may have implications for the success of further immunotherapy, according to research published...

...

07/13/2017

Journal of Clinical Pathways

Research in Review

High-Dose Chemo Yields Similar Survival Outcomes in Patients With AML

06/22/2017

JCP Editors

Standard induction chemotherapy is noninferior to high-dose chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML), according to new research published in the Journal of Clinical Oncology...

...

06/22/2017

Journal of Clinical Pathways

Research in Review

B-Cell Malignancy Provides Economic Burden to US Commercial Payers

05/30/2017

JCP Editors

The high economic burden of B-cell malignancies on US commercial insurers may impact future reimbursement decisions, according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017;...

The...

05/30/2017

Journal of Clinical Pathways

Research in Review

Leukemia Survival Outcomes Differ Between Sites of Care

04/11/2017

JCP Editors

Sites of care may help explain survival differences between children and adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), according to research published...

Sites...

04/11/2017

Journal of Clinical Pathways

Research in Review

Adding Androgens to Maintenance Therapy Improves Survival in Older Patients With AML

03/01/2017

JCP Editors

Maintenance therapy with androgens significantly improves survival in older patients with acute myeloid leukemia (AML) without increasing toxicity, according to research published in the Journal of Clinical Oncology...

...

03/01/2017

Journal of Clinical Pathways

Research in Review

Induction Therapy With Clofarabine Shows No Survival Benefit for AML

01/16/2017

JCP Editors

Adding clofarabine to standard induction therapy shows no effect on survival for patients with newly diagnosed acute myeloid leukemia (AML), according to a study published in Blood. Standard induction treatment with...

Adding...

01/16/2017

Journal of Clinical Pathways

Research in Review

Novel Biomarker Helps Detect Blood Cancer Responders to Chemotherapy

01/13/2017

JCP Editors

Expression of a cellular enzyme could predict the response of patients with acute myeloid leukemia (AML) to chemotherapy, according to new research. ----- Related Content Personalized Genomic Framework Predicts...

...

01/13/2017

Journal of Clinical Pathways

Research in Review

Leukemia Cancer Cells With TP53 Mutations Respond to Mild Chemotherapy

11/28/2016

JCP Editors

Patients with acute myeloid leukemia (AML) whose cells carry TP53 mutations may survive longer if they are treated with decitabine, according to a recent study in The New England Journal of...

...

11/28/2016

Journal of Clinical Pathways

Research in Review

Personalized Genomic Framework Predicts Treatment Outcomes in AML

12/10/2015

JCP Editors

Researchers have developed a novel prognostic framework using genomic sequencing data to assess risk in patients with acute myeloid leukemia (AML). Their work was presented at the American Society of Hematology (ASH)...

...

12/10/2015

Journal of Clinical Pathways